Pathology And Genetics Of Tumours Of The Nervous System

The second edition of this concise reference book was prepared by 106 authors from 21 countries and covers the neuro-oncological literature until January 2000. Diagnostic criteria, pathological features and associated genetic alterations are described in a strictly disease-oriented manner. Sections on more than 70 neoplasms and their variants include ICD-O codes, incidence, age and sex distribution, location, clinical signs and symptoms, pathology, genetics and predictive factors. New disease entities include the chordoid glioma of the third ventricle and the cerebellar liponeurocytoma. Inherited tumor syndromes involving the nervous system are dealt with in a separate chapter, combining diagnostic criteria, pathology and genetics.

WHO Classification of Tumours of the Central Nervous System is the revised fourth edition of the WHO series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. The book, prepared by 122 authors from 19 countries, contains more than 800 color images and tables, and more than 2800 references. This book is in the series commonly referred to as the "Blue Book" series.

This is the leading international professional reference text that also serves as a bench book, describing all aspects of the pathology of brain tumours - genetics, molecular biology, epidemiology, morphology, immunohistochemistry, diagnostic criteria and prognosis. Beautifully illustrated in colour throughout and comprehensively referenc

"WHO Classification of Tumours of the Central Nervous System" is the first volume of the 4th Edition of the World Health Organization series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria pathological features and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, incidence age and sex distribution, location, clinical signs and symptoms, pathology, genetics, and predictive factors. This book is in the series commonly referred to as the "Blue Book" series. The book prepared by 73 authors from 19 countries contains more than 400 color photographs, numerous X-rays, computed tomography (CT), magnetic resonance (MR) images, charts and more than 2,500 references. ."..The title of this book is typically modest. It is not only a classification of tumours of the central nervous system but an authoritative and explicit account of this group of tumours...This the fourth edition contains a number of distinct improvements on previous editions both in layout and content... One new feature is the clear account of the WHO's grading system its rationale and its application... New tumour entities are included...Newly recognized histological variants include pilomyxoid astrocytoma. Both anaplastic medulloblastoma and medulloblastoma with extensive nodularity have gained recognition in the classification... There are some differences in classification from the third edition most notably relating to anaplastic oligoastrocytoma. The change in emphasis follows cited differences in prognosis between mixed tumours with and without necrosis. Other changes are also apparent e.g. within the atypical teratoid/rhabdoid section mention of the INI-1 locus in the genetics section in the third edition has been expanded to include immunohistochemistry in the fourth edition. The fourth edition is unique in its clear-targeted and succinct style of presentation of tumors of the CNS... it will be of universal appeal in neuro-oncology and will most certainly form the main basis for diagnosis by multidisciplinary teams managing patients with tumors of the CNS." -- Nicki Cohen* and Roy O. Weller** *Specialist Registrar in Neuropathology Southampton University Hospital NHS Trust UK. ** Emeritus Professor of Neuropathology Southampton University UK in" Neuropathology and Applied Neurobiology. ."..Representing the first volume in the fourth edition series of the World Health Organization (WHO) Classification of Tumours this book provides a welcome mix of old and new. ... Perhaps the most noticeable improvement comes by way of a voluminous expansion in the genetics sections of the majority of tumor categories. This update parallels the recent explosion of research utilizing high-resolution genome screening and other molecular techniques. The authors have done an outstanding job in distilling the information housed in over 2,500 cited references into a reader friendly authoritative reference of CNS neoplasia. In summation, the current edition of the "WHO Classification of Tumours of the Central Nervous System" will serve as an indispensable textbook for all of those involved in the diagnosis and management of patients with tumors of the CNS and will make a valuable addition to libraries in pathology, radiology, oncology and neurosurgery departments. --"Journal of Neuropathology & Exp. Neurol."Contributors: Dr. Kenneth D. Aldape, Dr. Cristina R. Antonescu, Dr. Albert J. Becker, Dr. Jacklyn A. Biegel, Dr. Wojciech Biernat, Dr. Darell D. Bigner, Dr. Ingmar Blumcke, Dr. Fredrik T. Bosman, Dr. Sebastian Brandner, Dr. Daniel J. Brat, Dr. Herbert Budka, Dr. Peter C. Burger, Dr. Webster K. Cavenee, Dr. Leila Chimelli, Dr. V. Peter Collins, Dr. Catherine Daumas-Duport, Dr. Martina Deckert, Dr. Charles G. Eberhart, Dr. David W. Ellison, Dr. Charis Eng, Dr. Dominique Figarella-Branger, Dr. Gregory N. Fuller, Dr. Felice Giangaspero, Dr. Caterina Giannini, Dr. Hannu Haapasalo, Dr. Pierre Hainaut, Dr. Johannes A. Hainfellner, Dr. Volkmar H. Hans, Dr. Cynthia Hawkins, Dr. Stephen Hunter, Dr. Anne Jouvet, Dr. Alexander R. Judkins, Dr. Paul Kleihues, Dr. Andrey Korshunov, Dr. Johan M. Kros, Dr. Arielle Lellouch-Tubiana, Dr. Suet Yi Leung, Dr. Pawel Liberski, Dr. M. Beatriz S. Lopes, Dr. David N. Louis, Dr. Masao Matsutani, Dr. Roger E. Mclendon, Dr. Yoichi Nakazato, Dr. Hartmut P.H. Neumann, Dr. Ho-Keung Ng, Dr. Hiroko Ohgaki, Dr. Magali Olivier, Dr. Werner Paulus, Dr. Arie Perry, Dr. Torsten Pietsch, Dr. Karl H. Plate, Dr. Matthias Preusser, Dr. Guido Reifenberger, Dr. Federico Roncaroli, Dr. Marc K. Rosenblum, Dr. Elisabeth J. Rushing, Dr. Chitra Sarkar, Dr. Bernd W. Scheithauer, Dr. Davide Schiffer, Dr. Sursala K. Shankar, Dr. Mehar C. Sharma, Dr. Dov Soffer, Dr. Figen Soylemezoglu, Dr. Anat O. Stemmer-Rachamimov, Dr. Ana Lia Taratuto, Dr. Tarik Tihan, Dr. Erwin G. Van Meir, Dr. Scott R. Vandenberg, Dr. Andreas Von Deimling, Dr. Alexander O. Vortmeyer, Dr. Pieter Wesseling, Dr. Otmar D. Wiestler, Dr. James M. Woodruff, Dr. David Zagzag"

****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** The WHO Classification of Tumours Central Nervous System Tumours is the sixth volume in the 5th edition of the WHO series on the classification of human tumors. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumors and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. What's new in this edition? The 5th edition, guided by the WHO Classification of Tumours Editorial Board, will establish a single coherent cancer classification presented across a collection of individual volumes organized on the basis of anatomical site (digestive system, breast, soft tissue and bone, etc.) and structured in a systematic manner, with each tumor type listed within a taxonomic classification: site, category, family (class), type, and subtype. In each volume, the entities are now listed from benign to malignant and are described under an updated set of headings, including histopathology, diagnostic molecular pathology, staging, and easy-to-read essential and desirable diagnostic criteria. Who should read this book? Pathologists Neuro-oncologists Neuroradiologists Medical oncologists Radiation oncologists Neurosurgeons Oncology nurses Cancer researchers Epidemiologists Cancer registrars This volume Prepared by 199 authors and editors Contributors from around the world More than 1100 high-quality images More than 3600 references WHO Classification of Tumours Online The content of this renowned classification series is now also available in a convenient digital format by purchasing a subscription directly from IARC here.

The classification of brain tumors is up-dated using magnetic resonance spectroscopy technology. The role of cellular immortality in brain tumors is reviewed. Tumor to tumor metastases are a common occurrence; for example, , brain metastasis from breast cancer, lung cancer, and renal cancer is discussed. Genetic profiling and treatment (including neurosurgery) of such brain cancers are explained. Breast cancer patients treated with certain drugs (e.g., capecitabine and lapatinib can develop CNS tumors. Role of brain tumor suppressor genes (e.g., NRP/B gene) is pointed out. Biomarkers used to diagnose brain malignancies are explained in detail. A number of imaging modalities used for diagnosing and assessing the effectiveness of treatments of brain tumors are presented. The imaging methods discussed include MRI, PET, CT, MRSi, and SPECT. Also, is discussed the impact of PET using radiolabeled amino acids on brain tumors.